Paola Cavalcante

Dr. Paola Cavalcante

Neurology IV - Neuroimmunology and Neuromuscular Diseases Unit, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, 20133 Milan, Italy
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2005 in Genomics
Verified
Journal Article
Closed access
DBDina Bellizzi
Dina Bellizzi
Giuseppina RoseGiuseppina Rose
Giuseppina Rose
Paola CavalcantePaola Cavalcante
Paola Cavalcante
GCGiuseppina Covello
Giuseppina Covello
Serena DatoSerena Dato
Serena Dato
GBGiovanna De Benedictis
Giovanna De Benedictis

25 May 2010 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
Paola CavalcantePaola Cavalcante
Paola Cavalcante
Barbara SerafiniBarbara Serafini
Barbara Serafini
BRBarbara Rosicarelli
Barbara Rosicarelli
LMLorenzo Maggi
Lorenzo Maggi
MBMassimo Barberis
Massimo Barberis
Renato MantegazzaRenato Mantegazza
Renato Mantegazza

1 September 2011 in Experimental Neurology
Verified
Journal Article
Closed access
SMstefania marcuzzo
stefania marcuzzo
IZIleana Zucca
Ileana Zucca
Alfonso MastropietroAlfonso Mastropietro
Alfonso Mastropietro
NRNicole Kerlero de Rosbo
Nicole Kerlero de Rosbo
Paola CavalcantePaola Cavalcante
Paola Cavalcante
PBPia Bernasconi
Pia Bernasconi

1 July 2013 in Autoimmunity Reviews
Verified
Journal Article
Closed access
Paola CavalcantePaola Cavalcante
Paola Cavalcante
PCPerrine Cufi
Perrine Cufi
Renato MantegazzaRenato Mantegazza
Renato Mantegazza
SBSonia Berrih-Aknin
Sonia Berrih-Aknin
PBPia Bernasconi
Pia Bernasconi
RPRozen Le Panse
Rozen Le Panse

1 October 2018 in Current Opinion in Neurology
Verified
Journal Article
Closed access
Renato MantegazzaRenato Mantegazza
Renato Mantegazza
PBPia Bernasconi
Pia Bernasconi
Paola CavalcantePaola Cavalcante
Paola Cavalcante
Purpose of review: The current article reviews the recent advances in the field of myasthenia gravis, which span from autoantibody profiling and pathogenic mechanisms to therapy innovation. The overview is highlighting specifically the data and the needs of targeted treatments in the light of precision medicine in myasthenia gravis.Recent findings: Novel data published recently further increased our knowledge on myasthenia gravis. The use of cell-based assays has greatly improved autoantibody detection in myasthenia gravis patients, and the mechanisms of action of these antibodies have been described. The role of Toll-like receptor activation in the generation of thymic alterations and anti-acetylcholine receptor autosensitization has been further investigated implementing our understanding on the relationships between innate immunity and autoimmunity. Additional studies have been focused on the alterations of T-cell/B-cell regulatory mechanisms in thymus and peripheral blood of myasthenia gravis patients. microRNAs and genetic factors are also emerging as key biomarkers in myasthenia gravis pathogenesis and prediction of drug efficacy in individual patients.Summary: The recent immunological and pathological findings in myasthenia gravis promise to improve myasthenia gravis treatment, via the development of more precise and personalized therapies.

1 January 2007 in Genomics
Verified
Journal Article
Closed access
DBDina Bellizzi
Dina Bellizzi
Serena DatoSerena Dato
Serena Dato
Paola CavalcantePaola Cavalcante
Paola Cavalcante
GCG. Covello
G. Covello
FCF. Di Cianni
F. Di Cianni
GBG. De Benedictis
G. De Benedictis